|Bid||5.52 x 800|
|Ask||9.10 x 1100|
|Day's Range||8.46 - 8.67|
|52 Week Range||6.66 - 16.37|
|Beta (5Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2021 - Aug 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Alpine (ALPN) signs a collaboration and supply deal with Merck to evaluate ALPN-202 in combination with the latter's Keytruda for treating various types of cancer.
SEATTLE, June 30, 2021--Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)